Healthcare -
Medical - Devices - NASDAQ - US
$ 12.13
1.39 %
$ 397 M
Market Cap
-12.57
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NeuroPace, Inc.
| Net Income | -27.1 M |
| Depreciation & Amortization | 1.77 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 10.3 M |
| Change in Working Capital | -5.45 M |
| Others | -3.24 M |
| Free Cash Flow | -18.3 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (27.1) | (33.0) | (47.1) | (36.1) | (24.3) | (30.0) |
| Depreciation & Amortization | 1.8 | 1.6 | 3.0 | 0.3 | 0.3 | 0.4 |
| Deferred Income Tax | 0 | 0 | 0 | 5.5 | 0.2 | (0.9) |
| Stock Based Compensation | 10.3 | 9.6 | 8.3 | 4.3 | 1.4 | 1.4 |
| Other Operating Activities | 2.6 | 4.6 | 3.7 | 1.1 | 2.9 | 4.0 |
| Change in Working Capital | (5.5) | (2.5) | (4.8) | 0.4 | (2.1) | 9 K |
| Cash From Operations | (17.9) | (19.7) | (36.9) | (24.6) | (21.6) | (25.0) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | (0.2) | (0.6) | (0.4) | 62 K | (0.5) |
| Other Items | 9.0 | 23.2 | 24.4 | (85.0) | (10.7) | 4.1 |
| Cash From Investing Activities | 9.0 | 23.0 | 23.8 | (85.4) | (10.8) | 3.6 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | (0.3) | 59 K | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | (4.1) | 24.5 | 21.3 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.1 | 0.2 | 0.5 | (2.5) | 62.2 | 42 K |
| Cash From Financing Activities | 4.3 | 8.1 | 0.5 | 102.5 | 55.0 | 21.4 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (4.6) | 11.5 | (12.6) | (7.4) | 22.6 | 38 K |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (18.3) | (19.9) | (37.5) | (25.0) | (21.7) | (25.5) |